Viral hepatitis is a serious public health problem. Its epidemiology is not precisely known in Morocco. Our objective was to assess the prevalence of HBV and HCV in a particular population of "blood donors" at the Regional Blood Transfusion Centre in Oujda. A retrospective study was conducted from May 1, 2013 to May 31, 2015. Thirty-one thousand nine hundred and fifty-two blood donors were tested. Antigen detection was made according to ELISA technique (Monolisa TM HBs Ag ULTRA). HCV research was performed by ELISA using the kit « Monolisa HCV Ag-Ab ULTRA ». 177 blood donors included, they are divided into 155 male (87.6%) and 22 female (12.4%) subjects with a ratio of 7. The average age was 37.64 ± 12 years.
Introduction
Hepatitis Virus B (HBV) and C (HCV) Viruses are a major public health problem worldwide. The World Health Organization (WHO) has estimated that 2 billion people have been infected with HBV and that approximately 350-400 million of them are chronic carries of HBV surface antigen (HBs Ag) [1, 2] . One hundred seventy (170 million) chronic HCV cases or 3% of the general population with a large geographical variation, have high risk of progression to cirrhosis and hepato-cellular carcinoma (HCC) [3] . It is estimated that more than 300,000 new cases of HCC are observed annually [3] .
One million people die each year from this disease because of the complications of chronic hepatitis and its consequences. The epidemiology of HBV and HCV infection in Morocco was studied.
Through a recent Moroccan study on the general population, the WHO has estimated that 3 million of people are chronically infected with hepatitis B or C. This figure is an alarming sign and reclasses Morocco among the countries where these diseases are endemic in the world [2, 3] . Before the introduction of the hepatitis B vaccination into the immunization program, the WHO concluded that Morocco has an intermediate prevalence of hepatitis B. Currently, the epidemiology of hepatitis B is not precisely known in our country [1, 2] . The main objective of this study was to assess the prevalence of HBV and HCV in a particular population of "Blood Donors" at the Regional Blood Transfusion Center of Oujda.
Methods
This is a retrospective descriptive study conducted at the Regional Score». The dosage of ALT was performed using a spectrophotometer brand «Multiskan Ascent» preset on the wavelength λ= 340nm. The reagent used is Fluitest ® GPT ALT (Figure 1 ).
Results
The prevalence of HBs Ag in blood donors was 0.55%. We included 177 blood donors who were divided into 155 male subjects (87,6%) and 22 female subjects (12,4%) with a sex ratio of 7 (Table 1) Hepatitis C: the HCV identification uses the following targets:
Serological markers: anti-HCV antibodies and HCV Ag; the viral nucleic acid: HCV RNA. In Morocco, only serology for hepatitis C is mandatory in blood donors [3] . In France, in addition the serology, the research for HCV RNA is obligatory for any blood donations [5] .
In our study, hepatitis C was identified by the research of antigen and hepatitis C antibodies. Kit "Monolisa HCV Ag-Ab ULTRA "has been used for screening and Kit" INNO -LIA HCV " for confirmation of HCV [5, 9] .
Sample: the population of blood donors
In our study, there was a significant increase in the number of blood [5] . This decrease is explained by the decrease in the need for blood products due to the revision of transfusion indications, the development of endoscopic procedures and autologous transfusion and preventive measures for donor selection. In our study, there was a predominance of male donors (72%), the number of female donors tripled in 2000 [11] .
The prevalence of HBs antigen
The global distribution of hepatitis B is highly variable, defining three geographical categories according to the prevalence of Hbs Ag [12] [13] [14] However, the prevalence of HBs Ag in our series is lower than that observed in Tunisia (3.6%) [16] and Mauritania (20.3%) [17] . There was also a significant decrease in the prevalence of HBs Ag among blood donors at the Regional Blood Transfusion Centre compared of
Oujda to a study conducted in the same centre by Dr. MOUSSI between 1996 and 2000, involving 28,941 blood donors, the target prevalence of HBs Ag of 1.8% [11] . This decrease in hepatitis B prevalence is due to the success of the national HBV vaccination program. In our study, the prevalence of HBs Ag was significantly higher among people aged 30 to 45 years (54.23% of HBs Ag + donors), followed by people aged 18 to 29 years (37.28%). This is because this age corresponds to a period of unprotected sexual activity, without tattoos and organ piercing. Our results are consistent with those obtained in Dr. MOUSSI's study [11] .
HCV prevalence
The WHO estimated that in 1999, 2.9% of the world's population was living with HCV infection [18] , knowing that no data were available in 57 countries. In Morocco, the exact prevalence of HCV infection is not well known. The WHO classifies Morocco in an area of average HCV prevalence, with a prevalence ranging from 1 to 2.49% [19] . In our study, the prevalence of HCV infection is 0.02%, which places the Oujda region in the low prevalence area, these results show a significant decrease in HCV prevalence compared to Dr Moussi´s study conducted at the same centre between 1996 and 2000 which indicated a prevalence of 0.42% [11] , we also note a low prevalence compared to studies on blood donors in different transfusion centers in Morocco with a maximum prevalence (1.1%) in Casablanca [19] .
Compared to the Maghreb countries, the prevalence of HCV positive serum in our series is lower than that observed in Tunisia (0.56%) [20] , Algeria (0.2%) [21] and Mauritania (1.1%) [17] . The figures in our series are in addition to those recorded in France with a prevalence of 0.03%, in an interesting study of 383,000 blood donors in 2012 [5] . In Africa, there is a very high heterogeneity of prevalence rates observed, ranging from 0% in Zambia to 26.6% in Egypt [22] . In our study, we found a higher prevalence of anti-HCV among female blood donors (83.33%), this
Page number not for citation purposes 4 predominance of women can be explained by some of the more common social risk practices among women (blood transfusion during delivery, tattooing). There is also a prevalence of 50% in the > 45 age group, which is also found in Dr. Moussi's study at the Regional Blood Transfusion Centre in Oujda (1996-2000) [11] .
Dosing of ALT
When the hepatitis C screening test is introduced, the search for increased ALT levels is not identifiable in terms of improving transfusion safety according to the WHO and for this reason, routine ALT testing of blood donors is not recommended [8] . In Morocco, the systematic determination of ALT in blood donors is obligatory [23] .
In France, the introduction of viral genomic screening of blood donors has cancelled the contribution of the ALT test to blood safety in relation to the known hepatotropic virus. The determination of ALT in 
Co-infection
In Dr MOUSSI's study conducted at the Regional Blood Transfusion
Centre in Oujda (1996 Oujda ( -2000 , no cases of HBs Ag (+)/HIV (+)/HIV (+) co-infection were reported. In Congo, a study was carried out by
F. BALEKA at the Blood Transfusion Centre in Kinshasa between
October and December 2000 on 373 blood donors and its objective is to clarify the co-infection that exists between the 3 viruses (HBV, HCV and HIV). 2 cases of HBs Ag /HIV co-infection were reported, representing a prevalence of 0.005% [24] . In our study, no cases of HCV/HIV co-infection were noted. This can be explained by the low number of HCV-positive donors. Our results are consistent with the results observed in the F. BALEKA study in Congo and in Dr. Moussi's study at the regional blood transfusion centre in Oujda. In our study, no cases of HBV/HCV co-infection were noted. This can be explained by the low prevalence of HCV in our series. In Morocco, the study found 0.13% co-infection with HBV and HCV [25] , compared to 0.03% co-infection in the study by Zouhdi et al. [26] . 
Conclusion
Chronic viral hepatitis is a real global health problem. In Morocco, the epidemiology of hepatitis B (HBV) and C (HCV) is not precisely known.
This study, which involves a large number of blood donors (31 952), assessed the local prevalence of HBV and HCV in this population.
According to this study, this with the available therapies, it is possible to achieve in the majority of patients a cure for HCV or prolonged disease control for HBV. The overall strategy for controlling hepatitis B is to control the disease. There are highly immunogenic vaccines available to prevent infections caused by hepatitis B, these infections are the first global diseases that can be prevented by vaccination in terms of morbidity and mortality. Viral hepatitis has been declared a public health priority by the WHO, along with HIV, tuberculosis and malaria. In Morocco, the introduction of the hepatitis B vaccine into the national immunization schedule has been obligatory for all newborns since 1999. That is a major step forward for our country.
The HBV vaccine is the first vaccine against a sexually transmitted infection and can be considered the first vaccine against cancer.
Ultimately, only screening and education, particularly among high-risk groups, will prevent this serious disease.
What is known about this topic
 Chronic viral hepatitis is a real global health problem;  In our study, the prevalence is currently estimated at 0.55% for HBV and 0.02% for HCV, which places Morocco among the low endemic countries;
 The prevention remains the most effective method to successfully control HBV and HCV infection.
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